Lynx1 Capital Management LP
DORADO, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$646.1M2026 Q3
Positions31
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.97.9%
What Changed This Quarter?
Top Holdings
GHRS
GH Research
48.2%
CGEM
Cullinan Therapeutics
21.3%
STOK
Stoke Therapeutics
15.7%
CCCC
C4 Therapeutics
3.9%
DTIL
Precision Biosciences
2.7%
AGIO
Agios Pharmaceuticals
2.4%
KRRO
Korro Bio
2.4%
NEUP
Neuphoria Therapeutics
0.5%
New / Increased
6 new · 6 increased
KZIANEW
Kazia Therapeutics
0.3%
SRZNNEW
Surrozen
0.1%
YARWNEW
Yarrow Bioscience
0.1%
IMCRNEW
Immunocore
0.1%
DYNNEW
Dyne Therapeutics
0.1%
DTIL
Precision Biosciences
2.7%
+190.2%
PRQR
Proqr Thrapeutics N
0.4%
+199.6%
CCCC
C4 Therapeutics
3.9%
+2.8%
Reduced / Exited
2 reduced · 2 sold out
AGIO
Agios Pharmaceuticals
2.4%
-86.1%
STOK
Stoke Therapeutics
15.7%
-3.5%
CGONEXIT
CG Oncology
0.3%
Vyne Therapeu…EXIT
Vyne Therapeutics
0.1%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.